Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...

Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the ...

In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 ...

US cardiorenal-focussed drugmaker Ardelyx (Nasdaq: ARDX) announced that Mike Kelliher, formerly executive vice president, ...

US biotech Trevi Therapeutics (Nasdaq: TRVI) has raised around $115 million in a public stock offering, giving it fresh ...

Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III ...

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

Texas-based ImmunoPrecise Antibodies (Nasdaq :IPA) a leader in AI-driven biotherapeutics, closed 22% higher Thursday. The ...

US gene therapy company RegeNXBio (Nasdaq: RGNX) yesterday announced new positive interim data from the Phase I/II AFFINITY ...

China-based Kelun-Biotech Biopharmaceutical (6990: HK) announced the placement of 5,918,000 H shares under its general ...